On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.
Pro-Leu-Gly-NH2 (MIF) inhibits the tremor induced by oxotremorine. Objective measurement of this tremor permits the drawing of a dose-effect curve. The inhibitory effect of the peptide increases linearly with increasing doses until an optimum is reached (between 30 and 40 mg/kg i.p.). At still higher doses the peptide is inactive. The same phenomenon is observed with analogues of MIF. This finding may have important bearings on the interpretation of clinical and experimental data obtained with MIF.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D009075:MSH Release-Inhibiting Hormone / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000494:pharmacology; D008297:Male; D051379:Mice; D010095:Oxotremorine / Q000037:antagonists & inhibitors*; D014202:Tremor / Q000139:chemically induced / Q000503:physiopathology*
D010095:Oxotremorine; D009075:MSH Release-Inhibiting Hormone